Abstract
Current evidence suggests a central role for antithrombotic agents such as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in the management of acute coronary syndromes (ACS). In patients with acute myocardial infarction, several studies have shown that LMWHs may represent an effective alternative to UFH as an adjunct to thrombolytic therapy and are not associated with an increased risk of major bleeding. In patients with unstable angina or non-ST-segment elevation myocardial infarction, trials have shown that the LMWH enoxaparin significantly reduces the risk of cardiovascular events, compared with UFH, while other trials have shown that the combination of enoxaparin and a glycoprotein IIb/IIIa antagonist is not associated with an excess risk of bleeding. However, LMWHs are significantly more expensive that UFH. Recently, newer antithrombotic agents such as fondaparinux and bivalirudin have shown equivalent efficacy to the heparins with less bleeding and appear clinically attractive. This review examines the current evidence for the efficacy and safety of antithrombotic agents in ACS.
Keywords: Heparin, acute coronary syndromes, low-molecular-weight heparin
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Antithrombotic Agents for Acute Coronary Syndromes
Volume: 6 Issue: 2
Author(s): Debabrata Mukherjee
Affiliation:
Keywords: Heparin, acute coronary syndromes, low-molecular-weight heparin
Abstract: Current evidence suggests a central role for antithrombotic agents such as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in the management of acute coronary syndromes (ACS). In patients with acute myocardial infarction, several studies have shown that LMWHs may represent an effective alternative to UFH as an adjunct to thrombolytic therapy and are not associated with an increased risk of major bleeding. In patients with unstable angina or non-ST-segment elevation myocardial infarction, trials have shown that the LMWH enoxaparin significantly reduces the risk of cardiovascular events, compared with UFH, while other trials have shown that the combination of enoxaparin and a glycoprotein IIb/IIIa antagonist is not associated with an excess risk of bleeding. However, LMWHs are significantly more expensive that UFH. Recently, newer antithrombotic agents such as fondaparinux and bivalirudin have shown equivalent efficacy to the heparins with less bleeding and appear clinically attractive. This review examines the current evidence for the efficacy and safety of antithrombotic agents in ACS.
Export Options
About this article
Cite this article as:
Mukherjee Debabrata, Antithrombotic Agents for Acute Coronary Syndromes, Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6 (2) . https://dx.doi.org/10.2174/187152508783955042
DOI https://dx.doi.org/10.2174/187152508783955042 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ultrasound Contrast Agents: Updated Data on Safety Profile
Current Pharmaceutical Design An Insight to Colon Targeted Drug Delivery System
Drug Delivery Letters Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio as Biomarkers for Cardiovascular Surgery Procedures: A Literature Review
Reviews on Recent Clinical Trials Endothelial Dysfunction and Coronary Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Coronary Atherosclerotic Disease Burden: An Emerging Endpoint in Progression / Regression Studies Using Intravascular Ultrasound
Current Drug Targets - Cardiovascular & Hematological Disorders From the Discovery of the Reactive Site of Inhibitors to Their Sequence to Reactivity Algorithm
Protein & Peptide Letters Anti-Inflammatory Therapeutic Approaches to Reduce Acute Atherosclerotic Complications
Current Pharmaceutical Biotechnology Review of Trans-Atlantic Cardiovascular Best Medical Therapy Guidelines – Recommendations for Asymptomatic Carotid Atherosclerosis
Current Vascular Pharmacology Dietary Prevention of Coronary Heart Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Novel Therapeutic Approaches Targeting Matrix Metalloproteinases in Cardiovascular Disease
Current Topics in Medicinal Chemistry Role of the Autonomic Nervous System in the Endothelial Dysfunction of the Metabolic Syndrome
Current Hypertension Reviews Management and Outcome of Heparin-Induced Thrombocytopenia in Pregnancy: A Systematic Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Peroxynitrite in the Cardiovascular Dysfunction of Septic Shock
Current Vascular Pharmacology Platelet-Monocyte Interactions - A Dangerous Liaison Linking Thrombosis, Inflammation and Atherosclerosis
Current Medicinal Chemistry Inflammasome in Dendritic Cells Immunobiology: Implications to Diseases and Therapeutic Strategies
Current Drug Targets Critical Roles of Insulin-Induced Senescence in Diabetic Vasculopathy
Vascular Disease Prevention (Discontinued) Management of Adult Active Tuberculosis Disease in Era of HIV Pandemic, Current Practices and Future Perspectives
Infectious Disorders - Drug Targets Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry Cell Death in Mammalian Development
Current Pharmaceutical Design